oral semaglutide fda Approves as the First Oral GLP-1 Pill? Novo's Rybelsus gains FDA expansion

If weight loss continues steadily and you have not yet reached your target, continuing to escalate toward 1.7 mg or 2.4 mg may yield additional benefits

Among currently available weight loss injections, liraglutide (Saxenda) demonstrates nausea in approximately 39% of users according to FDA labeling, though individual experiences vary

Mark the vial with final concentration and date immediately

Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation

Plain-language safety/monitoring guidance